16 articles for X Jiao
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

Amgen
Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Amgen
Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.

Amgen
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.

Amgen
Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.

Amgen
Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Amgen
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

TBA
Discovery and optimization of a series of liver X receptor antagonists.

Amgen
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.

Amgen
Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.

Amgen
Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors.

Jiangnan University
Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors.

Jiangnan University
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.

Amgen
Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.

Amgen Discovery Research
Discovery of a Highly Selective STK16 Kinase Inhibitor.

Chinese Academy of Sciences
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.

University of Wisconsin